What is SynVaccine?
SynVaccine is a pioneering computational design firm focused on viral engineering for critical medical applications. The company leverages its proprietary SynRAD platform to engineer viral-based products for gene therapy, cancer immunotherapy, and the treatment of infectious diseases. Their innovative approach targets healthcare providers and researchers in immunology and veterinary medicine, aiming to revolutionize treatment paradigms for a range of conditions.
How much funding has SynVaccine raised?
SynVaccine has raised a total of $1.7M across 1 funding round:
Private Equity
$1.7M
Private Equity (2017): $1.7M, investors not publicly disclosed
What's next for SynVaccine?
The substantial enterprise-level funding SynVaccine has attracted indicates a strong market validation and positions the company for significant scaling and further development of its groundbreaking technologies. This capital infusion is expected to accelerate the expansion of its product pipeline and enhance its market penetration in the rapidly evolving fields of gene therapy and infectious disease control.
See full SynVaccine company page
